A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

NCT04192344 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

276

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms
Tenosynovial Giant Cell Tumor

Interventions

DRUG: ABSK021

Sponsor

Abbisko Therapeutics Co, Ltd